La cadena de opciones muestra datos clave de las opciones de acciones de Molecular Templates a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Molecular Templates..

Molecular Templates (NASDAQ:MTEM) Bolsa, Cadena de Opciones

Molecular Templates

Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.

Molecular Templates Inc

Traders seeking short-term opportunities in a changing economy are turning to leveraged and inverse ETFs as tools to capitalize on market shifts, particularly following the recent election. At the most recent virtual <a href="https://www.benzinga.com/events/">Benzinga</a> boot camp hosted by Direxion, analysts spotlighted strategies and trends driving interest in these financial instruments while emphasizing their role in tactical trading.
During the session, Gianni Di Poce, an analyst at The Mercator LLC, and Eliott Wellenbach, a senior vice president and institutional ETF strategist at Direxion, discussed the performance of leveraged ETFs in semiconductors, Chinese markets, and single-stock opportunities.
See Also: <a href="https://www.benzinga.com/24/12/42528079/this-high-yield-dividend-etf-is-undergoing-a-harsh-reversal-signaling-bearish-trends-here-what-you-need-to-know">This High Yield Dividend ETF Is Signaling Bearish Trends: Is Trouble Brewing?</a>
<h3 class="wp-block-heading">Why Traders Are Watching Semiconductors</h3>
The semiconductor industry remains a focal point for traders as artificial intelligence and quantum computing developments continue to shape the market. Di Poce pointed to the Philadelphia Semiconductor Index as a case study, noting its upward trend.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Trading the New Trump Era: Leveraged ETF Bets for a Changing Economy" width="500" height="281" src="https://www.youtube.com/embed/r42G6s6ysEw?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
"When looking at trends, higher highs and higher lows indicate where the bigger directional moves are likely to occur," Di Poce said. He emphasized the value of Direxion's triple-leveraged SOXL ETF for bullish opportunities while also recognizing potential on the bearish side with SOXS, depending on short-term market movements.
Wellenbach added context from fund flows, explaining that SOXL has been among the top ETFs for inflows this year, reflecting investor confidence in semiconductor performance. "SOXL is our second-largest fund by assets under management," he said, acknowledging recent weekly outflows as traders locked in profits.
<h3 class="wp-block-heading">China's Rebound Draws Interest</h3>
China's markets have also garnered attention after periods of volatility and downtrends. Di Poce highlighted the FTSE China 50 Index, explaining how stimulus measures and broader monetary shifts have contributed to a potential trend reversal.
"You had lower lows and lower highs for months, but that began to change earlier this year," Di Poce noted, pointing to recent higher lows as a signal of recovery. Direxion's YINN, a bullish China ETF, has seen notable inflows, aligning with the market's upward trajectory.
Wellenbach echoed this sentiment, adding that YINN became one of Direxion's top-performing funds following the Federal Reserve's rate adjustments. "The September easing helped shift global monetary flows, and traders recognized that opportunity," he said.
<h3 class="wp-block-heading">Single-Stock ETFs: A Growing Tool</h3>
Another focus of the session was single-stock ETFs. Di Poce discussed opportunities in high-profile names like Apple, Alphabet, and Tesla, noting their recent technical patterns.
"Apple broke through resistance and hit new highs, while Tesla confirmed its bull trend after months of declines," Di Poce said. Leveraged funds like AAPU for Apple and TSLU for Tesla offer traders tools to take short-term positions on individual stocks.
Wellenbach highlighted the increasing popularity of these ETFs, saying, "We've seen assets in single-stock funds grow from $1 billion to $6 billion this year as traders look for ways to express short-term convictions or hedge concentrated positions."
<h3 class="wp-block-heading">Education And Strategy Remain Crucial</h3>
Both analysts emphasized the importance of understanding how leveraged ETFs function throughout the event. Wellenbach stressed their role as short-term tools and warned traders against a buy-and-hold approach due to the funds' daily rebalancing.
"These are powerful instruments, but you need to know what you own and how they work," Wellenbach said. Di Poce echoed this caution, reminding traders to manage risk. "Leverage can amplify gains, but it can also amplify losses. You can't afford to stay wrong for long."
Now Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42529095/bitcoin-crash-could-trigger-stock-market-decline-in-2025-warns-expert-im-very-worried-that-people-overextended-themselves">Bitcoin Crash Could Trigger Stock Market Decline In 2025, Warns Expert</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

ETFs

AAPU

SOXL

Direxion Daily Semiconductor Bear 3X Shares

SOXS

YINN

EXCLUSIVE: Leveraged ETFs Offer Short-Term Edge As Traders Eye Semiconductors, China, And Quantum Tech In Post-Election Market

UBS analyst Seth Gilbert initiates coverage on Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) with a Neutral rating and announces Price Target of $32.

News

Price Target

Initiation

Analyst Ratings

OTEX

UBS Initiates Coverage On Open Text with Neutral Rating, Announces Price Target of $32

WIIM

WIMI

WiMi Hologram shares are trading higher after the company announced it's developing a new design solution for simulating quantum computing concepts using FPGA

U.S. retail sales exceeded expectations in November, highlighting consumers&#8217; continued resilience in spending as <a href="https://www.benzinga.com/news/econ-s">the holiday season began.</a>
Retail and food services sales rose to $724.6 billion in November, a 0.7% increase from October, according to seasonally adjusted advance estimates released Tuesday.
The monthly growth outpaced market expectations of a 0.5% rise, based on consensus estimates from TradingEconomics.
<h3 class="wp-block-heading">Auto Sales Rocket</h3>
On a year-over-year basis, retail sales grew by a remarkable 3.8%, the highest since December 2023, up from the upwardly revised 2.9% in October.
Excluding motor vehicles and parts, retail sales advanced by 0.2% month-over-month, holding steady from October but missing expectations of 0.4%. When stripping out gasoline, motor vehicles, and parts, sales also rose by 0.2% in November, steady from October and below the expected 0.4%. 
Within spending categories, motor vehicle and parts recorded the largest monthly gain, with sales increasing 2.6% month-over-month and 6.5% year-over-year. 
Other increases were found in nonstore retailers, up 1.8% month-over-month and sporting goods, hobby, musical instrument, and book stores, up 0.9% on the month. 
On the other hand, miscellaneous store retailers registered the steepest monthly decline, with sales contracting 3.5%, followed by food services and drinking places, which saw sales fall 0.4%.
<h3 class="wp-block-heading">Market Reactions</h3>
The U.S. dollar index (DXY) which is tracked by the&nbsp;Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) strengthened by 0.2%, following the data. 
Treasury yields ticked higher, with the 10-year benchmark up by 2 basis points to 4.42%. 
Futures on major U.S. equity indices edged lower in Tuesday&#8217;s premarket trading, with S&amp;P 500 contracts down 0.4% and the tech-heavy Nasdaq 100 slipping 0.5%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42514008/fed-poised-to-cut-interest-rates-by-0-25-this-week-heres-why-your-focus-should-shift-to-other-signals">Fed Poised To Cut Interest Rates By 0.25% This Week: Here&#8217;s Why Your Focus Should Shift To Other Signals</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Retail Sales

Econ #s

Economics

PowerShares DB US Dollar Index Bullish Fund

November Retail Sales Hit 11-Month Highs, Signal Strong Holiday Demand

GILD

Gilead Announces FDA Breakthrough Therapy Designation For Trodelvy For Second-Line Treatment Of Extensive-Stage Small Cell Lung Cancer

BMEA

Biomea Fusion shares are trading lower. The company reported Phase II results for Icovamenib in Type 2 diabetes.

Lakeside's Hupan Pharmaceutical Signs $1.5M Sales Agreement With Sinopharm Holding Hubei New Special Medicine

CoinShares CEO Jean-Marie Mognetti expressed confidence regarding the future of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ETFs and other cryptocurrencies such as Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) under the incoming administration of President-elect Donald Trump.
What Happened: Mognetti highlighted the substantial inflows into U.S. Bitcoin ETFs following the election. He noted that the Bitcoin ETF sector has witnessed 12 consecutive weeks of net inflows, a trend unseen since 2021. Mognetti anticipates that the new administration will maintain a positive stance towards cryptocurrency, potentially benefiting Ethereum and other digital coins, CNBC <a href="https://www.cnbc.com/video/2024/12/17/coinshares-ceo-on-the-expectations-crypto-will-continue-to-thrive-under-president-elect-trump.html">reported</a> on Tuesday. 
&#8220;The Trump administration coming up in January or February is nourishing a lot of hope,&#8221; Mognetti said.
See Also: <a href="https://www.benzinga.com/24/12/42495782/crypto-market-predicted-to-surge-to-all-time-highs-by-late-2025-but-a-30-drop-in-bitcoin-prices-could-come-first?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Crypto Market Predicted To Surge To All-Time Highs By Late 2025, But A 30% Drop In Bitcoin Prices Could Come First</a>
Mognetti also pointed out that the U.S. market has been lacking in crypto products since 2014, when the first application was submitted. The SEC has been cautious in approving new products, but Mognetti believes this is changing, allowing more issuers to properly introduce coins. As the market evolves, he expects increased investment demand for cryptocurrencies, driven by greater market education and regulatory support. 
Why It Matters: The optimism from Mognetti aligns with recent statements from Michael Saylor, co-founder of MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), who emphasized the<a href="https://www.benzinga.com/24/12/42522606/trump-is-serious-about-creating-a-bitcoin-reserve-says-microstrategys-michael-saylorurges-to-buy-btc-before-it-goes-up-by-100x"> incoming Trump administration&#8217;s seriousness</a> about establishing a U.S. strategic Bitcoin reserve. Saylor urged investors to &#8220;buy it now and own the future,&#8221; suggesting that capital will flow into digital assets and the Bitcoin network.
Furthermore, President-elect Trump has pledged to <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42480856/donald-trump-pledges-to-do-something-great-with-crypto-heres-what-hes-done-so-far">&#8220;do something great with crypto,&#8221;</a> indicating a significant shift in U.S. policy on digital assets. Trump emphasized the need for the U.S. to stay ahead of global competitors, particularly China, in embracing cryptocurrency. This potential policy shift could lead to increased regulatory support and market education, fostering a more favorable environment for cryptocurrencies like Bitcoin and Ethereum. 
Price Action: According to <a href="https://pro.benzinga.com">Benzinga Pro</a> data, at 8:42 am ET, Bitcoin was up at $1,07,469.30 while Ethereum was trading at $4,008.83. Meanwhile, Bitcoin based ETFs were also seeing an upward movement. Bitwise Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITB#NYSE">BITB</a>) was up by 1.56%, iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) was up by 1.66% and Grayscale Bitcoin Trust (Btc) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#NYSE">GBTC</a>) was trading 1.40% higher.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42496852/benzinga-bulls-and-bears-tesla-nvidia-microstrategy-dollar-tree-and-dogecoin-prediction-of-18-in-wild-scenario?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla, Nvidia, MicroStrategy, Dollar Tree, And Dogecoin Prediction Of $18 In &#8216;Wild&#8217; Scenario: Benzinga Bulls</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Markets

General

$BTC

$ETH

$SOL

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

GBTC

IBIT

MSTR

CoinShares CEO Optimistic About Bitcoin ETFs, Ethereum Under Trump

LODE

Comstock shares are trading higher after the company announced it secured a $3 million incentive from Oklahoma to build headquarters and an advanced renewable fuel facility.

Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) shares are trading lower premarket today. On Monday, the company provided fourth-quarter guidance, expecting EPS of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42519618/nucor-announces-guidance-for-the-fourth-quarter-of-2024-earnings" rel="noreferrer noopener">$0.55 &#8211; $0.65 vs. the consensus of $0.86</a>.
The primary factor driving the expected earnings decline is lower earnings in the steel mills segment due to decreased<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> volumes and lower average selling prices</a>.
The company projects earnings in the steel products segment to decline, reflecting the same trends. However, the raw materials segment is anticipated to see an increase in earnings, excluding the impairment charge from the third quarter of 2024.
Nucor reported net earnings of&nbsp;$1.05&nbsp;per share in the&nbsp;third quarter&nbsp;of 2024 and&nbsp;$3.16&nbsp;per share in the&nbsp;fourth quarter&nbsp;of 2023.
Notably, during the <a target="_blank" href="https://www.benzinga.com//node/41439525" rel="noreferrer noopener">third-quarter earnings release</a>, Nucor stated that it expects the fourth quarter&nbsp;earnings per share to decrease compared to $1.05&nbsp;reported for the&nbsp;third quarter amid decreased steel mill segment earnings caused by lower average selling prices and decreased volumes.
In the fourth quarter, Nucor repurchased around 2.1 million shares at an average price of $149.81 per share, bringing the total year-to-date repurchases to 13.1 million shares at an average price of $168.75 per share.
Nucor has returned over $2.73 billion to stockholders through share repurchases and dividend payments so far this year.
In October, the company reported quarterly adjusted earnings of $1.49 per share, which beat the analyst consensus estimate of $1.47 and revenue of $7.44 billion, which beat the analyst consensus estimate of $7.28 billion.
Nucor plans to release its fourth-quarter results on&nbsp;Monday, January 27, 2025.
Investors can gain exposure to the stock via&nbsp;VanEck Steel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLX#NYSE">SLX</a>)&nbsp;and First Trust Materials AlphaDEX Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXZ#NYSE">FXZ</a>).
Price Action: NUE shares are down 1.51% at $122.29 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42527692" target="_blank" rel="noreferrer noopener">Mission Accomplished: Lockheed Martin&#8217;s GPS III SV07 Successfully Deployed</a></li>
</ul>

Equities

Guidance

Movers

Nucor's Q4 Guidance Misses The Mark, Hit By Steel Slowdown; Stock Slides

FREY

FREYR Battery shares are trading higher after the company announced its CFO disclosed via a Form 4 filing a purchase for 549,862 shares of company stock at an average price of $1.64 per unit.

Sea's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) short percent of float has risen 13.71% since its last report. The company recently reported that it has 15.32 million shares sold short, which is 5.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sea Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734443121_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sea has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Sea's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sea's peer group average for short interest as a percentage of float is 2.73%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Sea's Recent Short Interest

Lumen Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) short percent of float has risen 8.96% since its last report. The company recently reported that it has 70.31 million shares sold short, which is 9.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lumen Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734443116_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lumen Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Lumen Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lumen Technologies's peer group average for short interest as a percentage of float is 5.60%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LUMN

Looking Into Lumen Technologies's Recent Short Interest

CORRECTION: Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Overweight rating and announces Price Target of $8. -Analyst Firm Updated

ESPR

CORRECTION: Cantor Fitzgerald Initiates Coverage On Esperion Therapeutics with Overweight Rating, Announces Price Target of $8 -Analyst Firm Updated

Monolithic Power Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NYSE">MPWR</a>) short percent of float has fallen 16.74% since its last report. The company recently reported that it has 2.09 million shares sold short, which is 5.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Monolithic Power Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734443111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Monolithic Power Systems has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Monolithic Power Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Monolithic Power Systems's peer group average for short interest as a percentage of float is 4.89%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MPWR

Looking Into Monolithic Power Systems's Recent Short Interest

QUBT

Quantum Computing shares are trading higher after the company announced it was awarded a prime contract by NASA to apply Dirac-3 for imaging and data processing support.

Contracts

Quantum Computing, Inc. Awarded Prime Contract By NASA To Apply Dirac-3 To Support NASA's Imaging And Data Processing

ELVA

Electrovaya shares are trading lower after the company announced a secondary offering of 5,175,000 shares priced at $2.15 per unit.

Expects product gross margin to range between 47% and 51% in fiscal year 2025, compared to product gross margin of 31% in fiscal year 2024.

Health Care

NMTC

NeuroOne Medical Expects Product Revenue Of $8M-$10M In Fiscal Year 2025, Representing An Increase Of Between 132% And 190% When Compared To Product Revenue Of $3.5M In Fiscal Year 2024

ASPS

Altisource shares are trading higher after the company announced it secured an agreement that will reduce its debt by $58 million.

Molecular Templates GAAP EPS of $0.08, revenue of $11.09M beats by $5.19M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Molecular Templates (NASDAQ:<a href="https://investorplace.com/stock-quotes/mtem-stock-quote/">MTEM</a>) just reported results for the first quarter of 2024.<ul><li>Molecular Templates reported earnings per share of 8 cents. This was above the analyst estimate for EPS of -78 cents.</li><li>The company reported revenue of $11.09 million.</li><li>This was 87.90% better than the analyst estimate for revenue of $5.90 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/mtem-stock-earnings-molecular-templates-for-q1-of-2024/">MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!



Moving stocks this morning are earnings reports, new contracts, a CEO change and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Cue Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/hlth-stock-quote/">HLTH</a>) stock is rocketing more than 49% despite <a href="https://investorplace.com/2024/05/why-is-cue-health-hlth-stock-down-40-today/">plans to close its business</a>.</li>



<li>Smart for Life (NASDAQ:<a href="https://investorplace.com/stock-quotes/smfl-stock-quote/">SMFL</a>) shares are soaring over 48% after <a href="https://www.nasdaq.com/press-release/smart-for-life-announces-updates-on-successful-completion-of-restructuring-program">completing a restructuring program</a>.</li>



<li>Molecular Templates (NASDAQ:<a href="https://investorplace.com/stock-quotes/mtem-stock-quote/">MTEM</a>) stock is surging more than 30% without any clear news this morning.</li>



<li>OneMedNet (NASDAQ:<a href="https://investorplace.com/stock-quotes/onmd-stock-quote/">ONMD</a>) shares are increasing over 29% after <a href="https://finance.yahoo.com/news/onemednet-inks-agreement-global-top-200500512.html">signing a new contract</a>.</li>



<li>Kintara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktra-stock-quote/">KTRA</a>) stock is rising more than 26% alongside heavy pre-market trading.</li>



<li>Cheche (NASDAQ:<a href="https://investorplace.com/stock-quotes/ccg-stock-quote/">CCG</a>) shares are gaining over 21% with its <a href="https://www-thailand--business--news-com.webpkgcache.com/doc/-/s/www.thailand-business-news.com/thailand-prnews/cheche-group-reports-first-quarter-2024-unaudited-financial-results">latest earnings release</a>.</li>



<li>Verb Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/verb-stock-quote/">VERB</a>) stock is climbing more than 17% with strong early morning trading.</li>



<li>Nexalin Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/">NXL</a>) shares are jumping over 15% despite a lack of news.</li>



<li>Burlington Stores (NYSE:<a href="https://investorplace.com/stock-quotes/burl-stock-quote/">BURL</a>) stock is getting a more than 14% boost with its <a href="https://finance.yahoo.com/news/burlington-stores-inc-reports-first-104500806.html">Q1 earnings report</a>.</li>



<li>C3.ai (NYSE:<a href="https://investorplace.com/stock-quotes/ai-stock-quote/">AI</a>) shares are up over 14% after <a href="https://www.investors.com/news/technology/c3-ai-stock-ai-stock-c3-ai-earnings-news-q12024/">beating Q1 estimates</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>NovaBay Pharmaceuticals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/nby-stock-quote/">NBY</a>) stock is plummeting more than 40% alongside <a href="https://www.nasdaq.com/press-release/novabay-pharmaceuticals-announces-approval-all-proposals-its-2024-annual-meeting">annual shareholder meeting plans</a>.</li>



<li>UiPath (NYSE:<a href="https://investorplace.com/stock-quotes/path-stock-quote/">PATH</a>) shares are diving over 30% on <a href="https://www.nasdaq.com/press-release/uipath-re-appoint-daniel-dines-chief-executive-officer-rob-enslin-steps-down-ceo-and">a CEO change</a>.</li>



<li>Innovative Eyewear (NASDAQ:<a href="https://investorplace.com/stock-quotes/lucy-stock-quote/">LUCY</a>) stock is retreating more than 21% on a <a href="https://finance.yahoo.com/news/innovative-eyewear-inc-announces-2-184300125.html">new direct offering</a>.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) shares are tumbling over 18% without any obvious news today.</li>



<li>SCWorx (NASDAQ:<a href="https://investorplace.com/stock-quotes/worx-stock-quote/">WORX</a>) stock is taking a more than 16% beating this morning.</li>



<li>Salesforce (NYSE:<a href="https://investorplace.com/stock-quotes/crm-stock-quote/">CRM</a>) shares are dropping over 16% on <a href="https://finance.yahoo.com/video/salesforce-stock-sinking-q2-earnings-202330512.html">poor Q2 guidance</a>.</li>



<li>Onconetix (NASDAQ:<a href="https://investorplace.com/stock-quotes/onco-stock-quote/">ONCO</a>) stock is decreasing close to 16% after an unexpected rally yesterday.</li>



<li>Sharps Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/stss-stock-quote/">STSS</a>) shares are falling more than 14% <a href="https://investorplace.com/2024/05/why-is-sharps-technology-stss-stock-up-194-today/">following a recent rally</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) stock is slipping over 13% today.</li>



<li>Agilent Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/a-stock-quote/">A</a>) shares close out our pre-market stock movers down over 13% on <a href="https://finance.yahoo.com/news/agilent-reports-q2-earnings-key-220003997.html">fiscal Q2 earnings</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-may-30th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
There are risks associated with any investment &ndash; there&rsquo;s no such thing as a surefire investment, although tools like the Portfolio Grader can make your life easier when looking for stocks to buy and those to avoid. One of the riskiest investments are in F-rated <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>, and those should be avoided at all costs when you&rsquo;re considering your portfolio.



Penny stocks are low-priced securities, but they really don&rsquo;t cost a penny. Instead, they are shares of stocks that are priced at less than $5 &ndash; still a pittance compared to some of the top names in the market. While some large companies fall into penny stock territory, penny stocks often represent small, less established companies. While the low cost and potential for high returns can make penny stocks appealing to some investors, they come with significant risks, especially when dealing with F-rated penny stocks.



F-rated penny stocks represent companies that have the lowest ratings from the Portfolio Grader based on factors like earnings performance, growth, trading momentum and analyst sentiment. These ratings show poor financial health, unstable management, or dubious business practices.



Another huge issue with F-rated penny stocks is that they are volatile. You have to have a high risk tolerance because these stocks often experience significant price swings within short periods, driven by speculative trading and limited market liquidity. 



It is very difficult to predict the day-to-day price movements of penny stocks, which means a bad bet can wipe out your investment pretty quickly.



The names on this list all get &ldquo;F&rdquo; ratings in the Portfolio Grader, and should be avoided this month.



<h2>Tonix Pharmaceuticals (TNXP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/">TNXP</a>) is a biopharmaceutical company based in New Jersey. The company works on created drugs and therapies to treat disorders of the central nervous system.



It currently has a drug candidate in Phase 3 testing to treat fibromyalgia, and a treatment in Phase 2 trials that would treat long Covid-19 symptoms.



But one of the challenges of investing in pharma companies is the expense. Research and development takes a lot of money, as does the clinical trials. And even after all that, there&rsquo;s never a guarantee that the drug will come to market. That&rsquo;s why investing in a penny pharma stock is particularly dangerous.



Tonix stock fell by 40% in June when it announced a <a href="https://investorplace.com/2024/06/why-is-tonix-pharmaceuticals-tnxp-stock-down-40-today/">proposed public offering</a> to raise money for its continued funding. Investors don&rsquo;t like it when their stock is diluted, andthis is the second time. Tonix also completed a 1-for-32 reverse stock split in June to try oto keep the stock price up.



Even when that reverse split, TNXP stock is barely over $1 per share again. The stock is down 91% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Nauticus Robotics (KITT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-fingers-300x169.jpg" alt="Image of a penny held between two fingers with a white indoor background. Dividend-Paying Penny Stocks"><div>Source: Shutterstock</div></div>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) is an interesting penny stock. The company makes underwater robots and software that is used by energy, aquaculture and security systems.



Nauticus markets itself as a solution that can help companies manage and maintain offshore wind farms. It says that its robots reduces the need for divers and topside personnel.



But being an interesting company and being a good investment doesn&rsquo;t go hand-in-hand. Nauticus only has a market capitalization of $15 million, and a stock price of roughly 15 cents per share. 



That&rsquo;s why the board held a <a href="https://ir.nauticusrobotics.com/sec-filings/all-sec-filings">special meeting on June 17</a> in which it increased the number of unissued common stock shares from 625 million to 5 billion shares. And it also got shareholders to sign off on a reverse stock split that could be as little as 1-to-6 or as much as 1-to-70 shares.



KITT stock popped briefly on the news before returning to its depressed levels. Meanwhile, earnings results for the first quarter showed only $500,000 in revenue compared to $2.8 million a year ago. 



The adjusted net loss was $7.4 million for the quarter, which was an improvement from the first quarter a year ago when it lost $10.7 million.



KITT is in rough shape, down 78% this year. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Mullen Automotive (MULN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/muln_mullen_1600-300x169.png" alt="The Mullen (MULN) Five vehicle is displayed at the 2021 LA Auto Show media day in Los Angeles, November, 18, 2021."><div>Source: Ringo Chiu / Shutterstock.com</div></div>I&rsquo;ve been pretty hard on Mullen Automotive (NASDAQ:<a href="https://investorplace.com/stock-quotes/muln-stock-quote/">MULN</a>), which is an electric vehicle company that&rsquo;s struggling to gain relevance. 



I wasn&rsquo;t impressed in 2023 when the company enacted three reverse stock splits, including a 1-for-100 split in December, just so it could remain listed on the Nasdaq.



But Mullen is making a legitimate effort to remake its business by becoming a manufacturer of commercial EVs. It signed a new deal to supply 40 commercial vehicles to a company in&nbsp;<a href="https://finance.yahoo.com/news/mullen-automotive-secures-major-european-183010622.html">Switzerland</a>.&nbsp;It also signed a franchise <a href="https://seekingalpha.com/news/4114510-mullen-enters-new-dealership-and-gets-initial-order?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">agreement</a> with Eco Auto, a dealership located in Boston, that&rsquo;s focused on EVs.



I appreciate that Mullen is trying to salvage some value. It invoiced $16.3 million in vehicles in the second quarter of fiscal 2024. But losses are still massive, with a net loss of the quarter of $235.3 million and a cash burn of $120 million.



MULN stock is down 82% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Avalon GloboCare (ALBT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-finding-magnify-300x169.jpg" alt="A hand holding a magnifying glass over pennies. under-$1 stocks to buy. penny stocks to buy"><div>Source: Shutterstock</div></div>Avalon GloboCare (NASDAQ:<a href="https://investorplace.com/stock-quotes/albt-stock-quote/">ALBT</a>) is a biotechnology company that develops diagnostic and clinical laboratory products. It&rsquo;s working on a commercial Breathalyzer system that would be a handheld device that can detect acetone levels.



It also has a research project with the Massachusetts Institute of Technology to create a QTY code protein design platform.



The advancements are interesting, but the company has some issues at well. In May it got warning from Nasdaq that as of May 22, the company had not yet filed its first quarter report. <a href="https://www.avalon-globocare.com/investors/sec-filings/quarterly-reports">When the report finally came out</a>, it showed a net loss of $1.36 million, or 12 cents per share, versus a loss of $2.91 million and 29 cents per share in the same quarter a year ago.



Avalon has just over $300,000 in cash on hand, so it will have to be careful with its finances if its going to complete its projects.



ALBT stock is down 14% this year and gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>ChargePoint Holdings (CHPT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/04/chpt-stock-2-300x169.jpg" alt="EV stocks: A close-up shot of a ChargePoint charging station."><div>Source: YuniqueB / Shutterstock.com</div></div>ChargePoint Holdings (NYSE:<a href="https://investorplace.com/stock-quotes/chpt-stock-quote/">CHPT</a>) is a good company with a good idea and it simply got outplayed. 



The Biden administration is all-in on building out the national infrastructure to power electric vehicles, and it made perfectly good sense for a company like ChargePoint to be in the forefront of making that happen.



But then there&rsquo;s Tesla (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>). Tesla has more than 40,000 charging stations and a powerful automotive company that has a vested interest in getting as many charging stations out there as possible. Tesla&rsquo;s charging stations are all branded with the company&rsquo;s name of course, making them a valuable marketing and advertising tool that just makes Tesla stronger.



Tesla also gets billions of dollars a year by partnering with other automotive companies so they can use the Tesla network.



Where does that leave ChargePoint? Not in a good place. <a href="https://s22.q4cdn.com/779683160/files/doc_financials/2024/2025/q1/CHPT_FY2025-Q1_FINAL.pdf">Earnings</a> for the first quarter of fiscal 2025 showed revenue of $107 million, down 18% from a year ago. The company posted a net loss of $71.8 million, which was a 10% improvement from last year.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-f-rated-penny-stocks-to-avoid-this-june/">7 F-Rated Penny Stocks to Avoid This June</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 F-Rated Penny Stocks to Avoid This June

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Molecular Templates (NASDAQ:<a href="https://investorplace.com/stock-quotes/mtem-stock-quote/">MTEM</a>) just reported results for the second quarter of 2024.<ul><li>Molecular Templates reported earnings per share of -$1.23. This was above the analyst estimate for EPS of -$1.44.</li><li>The company reported revenue of $572,000.</li><li>This was 33.02% better than the analyst estimate for revenue of $430,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mtem-stock-earnings-molecular-templates-for-q2-of-2024/">MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024

Molecular Templates GAAP EPS of -$1.23 misses by $0.12, revenue of $0.6M beats by $0.27M

Bristol, Prime Medicine in deal to develop T-cell therapies

Molecular Templates (MTEM) announced that it has received an expected deficiency notification letter from Nasdaq on November 25. The notice indicat...

Molecular Templates receives noncompliance notice from Nasdaq

Molecular Templates ( ($MTEM) ) has issued an announcement. Jason Kim has resigned as the Company's President, CFO, and Treasurer, effective Decemb...

Molecular Templates Announces Key Leadership Transition

Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.

Top Biotech Short Squeeze Stocks

ALBT

BURL

CHPT

CRVO

FCEL

HLTH

KITT

KTRA

LUCY

MTEM

MULN

ONCO

ONMD

PATH

PHAT

PRME

SAVA

SMFL

SNOA

STSS

TNXP

TSLA

VERB

WORX

Press Releases

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Molecular Templates, Inc. Provides Interim Update

Financing

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

Earnings

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism

Molecular Templates, Inc. Reports First Quarter  2024 Financial Results and Corporate Update

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

Comments

Molecular Templates

Molecular Templates (MTEM) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL